Efficacy and safety of telmisartan vs. losartan in control of mild-to-moderate hypertension: A multicentre, randomised, double-blind study

International Journal of Clinical Practice, Supplement

Volumn , Issue 145, 2004, Pages 46-49

  Zhu, J R ^a   Bai, J ^a   Cai, N S ^a   Tang, B ^a   Fan, W H ^b   Guo, J Z ^c   Ke, Y N ^d   Guo, J X ^e   Sheng, L H ^f   Lu, Z Y ^g   Cheng, N N ^a  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^d Sino Japan Friendship Hospital   (China)

^e PEKING UNIVERSITY   (China)

^f China Japan Friendship Hospital   (China)

^g HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Angiotensin II receptor blocker; Antihypertensives; Hypertension; Losartan; Telmisartan

Indexed keywords

LOSARTAN; TELMISARTAN;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BINDING; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE;

ADOLESCENT; ADULT; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION; LOSARTAN; MALE; MIDDLE AGED;

EID: 10344250394     PISSN: 1368504X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Ueshima H, Zhang XH, Choudhury SR. Epidemiology of hypertension in China and Japan. J Hum Hypertens 2000; 14: 765-9.
2. Zhao W, Chen J. Implications from and for food cultures for cardiovascular disease: diet, nutrition and cardiovascular diseases in China. Asia Pac J Clin Nutr 2001; 10: 146-52.
3. Li W, Gueyffierd F, Liu GZ, et al. The effect of antihypertensive treatment on cardiovascular events - a meta-analysis of four clinical trials in China. Biomed Environ Sci 2001; 14: 341-9.
4. Elliott WJ. Therapeutic trials comparing angiotensin converting enzyme inhibitors and angiotensin II receptor blockers. Curr Hypertens Rep 2000; 18: 402-11.
5. Siragy H. Angiotensin II receptor blockers: review of the binding characteristics. Am J Cardiol 1999; 84 (Suppl. 10A): 3S-8S.
6. Song JC, White CM. Pharmacologic, pharmacokinetic, and therapeutic differences among angiotensin II receptor antagonists. Pharmacotherapy 2000; 20: 130-9.
7. Oparil S. Newly emerging pharmacologic differences in angiotensin II receptor blockers. Am J Hypertens 2000; 13 (1 Part 2): 18S-24S.
8. Burnier M, Angiotensin II type 1 receptor blockers. Circulation 2001; 103: 904-12.
9. Sharpe M, Jarvis B, Goa KL. Telmisartan: a review of its use in hypertension. Drugs 2001; 61: 1501-29.
10. Neutel JM, Smith DHG. Dose response and antihypertensive efficacy of the AT1 receptor antagonist telmisartan in patients with mild to moderate hypertension. Adv Ther 1998; 15: 206-17.
11. Smith DH, Matzek KM, Kempthorne-Rawson J. Dose response and safety of telmisartan in patients with mild to moderate hypertension. J Clin Pharmacol 2000; 40: 1380-90.
12. White WB. Relevance of blood pressure variation in the circadian onset of cardiovascular events. J Hypertens 2003; 21 (Suppl. 6): S9-S15.
13. Wienen W, Enterzoth M, van Meel JCA, et al. A review on telmisartan: a long-acting angiotensin II-receptor antagonist. Cardiovasc Drug Rev 2000; 18: 127-56.